Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

179
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
179
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

351
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
351
Teratogenicity01:07

Teratogenicity

2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory evolution after antenatal betamethasone dose reduction in very preterm neonates: a post hoc analysis of the BETADOSE trial.

European journal of pediatrics·2026
Same author

Hydrocortisone use in France: current practices in 2026.

European journal of pediatrics·2026
Same author

Assessment of neonatal intensive care units design and implementation of infant and family centered developmental care guidelines in France.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Development and validity evidence for the probabilistic reasoning test in undergraduate medical students.

BMC medical education·2026
Same author

School-age neurodevelopmental outcomes after non-emergency red blood cell transfusions in preterm infants: a propensity score-matched study from the Epipage 2 cohort.

European journal of pediatrics·2026
Same author

EXPRESS: Minute- and second-scale hippocampal network dysfunctions in the 3xTgAD mouse model of Alzheimer's disease are prevented by TSPO knockout.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026

Related Experiment Video

Updated: Jun 6, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.3K

Prophylactic low-dose hydrocortisone in neonates born extremely preterm: current knowledge and future challenges.

Olivier Baud1,2,3, Héloïse Torchin4,5, Marine Butin6,7

  • 1Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPE, French Institute for Medical Research and Health, Université Paris Cite, CRESS, INSERM, INRAE, Paris, France. olivbaud@gmail.com.

Pediatric Research
|November 26, 2024
PubMed
Summary

Prophylactic hydrocortisone in extremely low gestational age neonates (ELGANs) improves survival without bronchopulmonary dysplasia (BPD). While generally safe, optimal treatment strategies require further investigation.

More Related Videos

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

2.2K
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.6K

Related Experiment Videos

Last Updated: Jun 6, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.3K
Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

2.2K
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

5.6K

Area of Science:

  • Neonatal Medicine
  • Pediatric Pharmacology
  • Critical Care

Background:

  • Extremely low gestational age neonates (ELGANs) have immature adrenal glands, impairing their response to postnatal stress.
  • This immaturity can lead to serious complications like death and bronchopulmonary dysplasia (BPD).

Purpose of the Study:

  • To review the evidence on prophylactic low-dose hydrocortisone in ELGANs.
  • To assess its benefits, risks, and ongoing challenges in clinical practice.

Main Methods:

  • Systematic review of clinical trials and analysis of recent real-world data.
  • Discussion of implementation challenges and future research directions.

Main Results:

  • Prophylactic hydrocortisone reduces pre-discharge mortality and improves survival without BPD.
  • Benefits include patent ductus arteriosus (PDA) closure and improved cardiovascular stability.
  • Potential risks include increased spontaneous intestinal perforation and late-onset sepsis in specific subgroups.

Conclusions:

  • Prophylactic hydrocortisone is beneficial for ELGANs, improving survival outcomes.
  • Real-world data support trial findings, showing additional benefits without increased adverse events.
  • Further research is needed on optimal patient selection, timing, and duration of treatment.